- Home
- RENB vs SRTS Comparison
RENB vs SRTS Comparison
Compare RENB & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- SRTS
- Stock Information
- Founded
- RENB 2011
- SRTS 2010
- Country
- RENB United States
- SRTS United States
- Employees
- RENB N/A
- SRTS 35
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- RENB Health Care
- SRTS Health Care
- Exchange
- RENB Nasdaq
- SRTS Nasdaq
- Market Cap
- RENB 121.3M
- SRTS 88.7M
- IPO Year
- RENB N/A
- SRTS 2016
- Fundamental
- Price
- RENB $0.82
- SRTS $5.38
- Analyst Decision
- RENB
- SRTS Strong Buy
- Analyst Count
- RENB 0
- SRTS 2
- Target Price
- RENB N/A
- SRTS $13.00
- AVG Volume (30 Days)
- RENB 543.5K
- SRTS 569.4K
- Earning Date
- RENB 02-19-2025
- SRTS 02-05-2025
- Dividend Yield
- RENB N/A
- SRTS N/A
- EPS Growth
- RENB N/A
- SRTS 1266.06
- EPS
- RENB N/A
- SRTS 0.41
- Revenue
- RENB N/A
- SRTS $41,807,000.00
- Revenue This Year
- RENB N/A
- SRTS $9.09
- Revenue Next Year
- RENB N/A
- SRTS $22.30
- P/E Ratio
- RENB N/A
- SRTS $13.20
- Revenue Growth
- RENB N/A
- SRTS 71.31
- 52 Week Low
- RENB $0.40
- SRTS $2.91
- 52 Week High
- RENB $3.38
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- RENB 50.63
- SRTS 37.03
- Support Level
- RENB $0.69
- SRTS $5.41
- Resistance Level
- RENB $0.89
- SRTS $5.88
- Average True Range (ATR)
- RENB 0.07
- SRTS 0.50
- MACD
- RENB 0.02
- SRTS -0.12
- Stochastic Oscillator
- RENB 70.41
- SRTS 0.54
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.